We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+0.51%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.57B
AUM Growth
-$21.5M
Cap. Flow
+$32.3M
Cap. Flow %
1.25%
Top 10 Hldgs %
39.02%
Holding
197
New
37
Increased
49
Reduced
41
Closed
10

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$39M
2
JNJ icon
Johnson & Johnson
JNJ
+$21.2M
3
ESPR
Esperion Therapeutics
ESPR
+$13.9M
4
ABBV icon
AbbVie
ABBV
+$11.5M
5
BMY icon
Bristol-Myers Squibb
BMY
+$11.4M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$36.3M
2
AMGN icon
Amgen
AMGN
+$29.7M
3
BIIB icon
Biogen
BIIB
+$20.8M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$19.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.9M

Sector Composition

Rank Sector Weight
1 Healthcare 93.47%
2 Real Estate 2.71%
3 Financials 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
126
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$2.31M 0.09%
162,900
– –
ACHN
127
DELISTED
Achillion Pharmaceuticals
ACHN
$2.29M 0.09%
616,000
– –
TXMD icon
128
TherapeuticsMD
TXMD
$23.5M
$2.28M 0.09%
9,375
+975
+12% +$274K
CBAY
129
DELISTED
Cymabay Therapeutics
CBAY
$2.21M 0.09%
169,962
-40,000
-19% -$497K
HSIC icon
130
Henry Schein
HSIC
$9.77B
$2.11M 0.08%
40,035
– –
ACAD icon
131
Acadia Pharmaceuticals
ACAD
$4.43B
$2.1M 0.08%
93,689
-152,196
-62% -$4.21M
QTNT
132
DELISTED
Quotient Limited Ordinary Shares
QTNT
$2.08M 0.08%
11,062
+5,824
+111% +$1.05M
CHRS icon
133
Coherus Oncology
CHRS
$217M
$2M 0.08%
181,023
+91,023
+101% +$996K
LXRX icon
134
Lexicon Pharmaceuticals
LXRX
$1.03B
$1.98M 0.08%
231,054
-47,646
-17% -$441K
ABMD
135
DELISTED
Abiomed Inc
ABMD
$1.9M 0.07%
+6,514
New +$1.65M
HR
136
DELISTED
Healthcare Realty Trust Incorporated
HR
$1.88M 0.07%
68,000
– –
PTGX icon
137
Protagonist Therapeutics
PTGX
$8.79B
$1.88M 0.07%
219,042
+136,220
+164% +$2.57M
DERM
138
DELISTED
Dermira, Inc.
DERM
$1.87M 0.07%
234,200
-34,300
-13% -$747K
TLGT
139
DELISTED
Teligent, Inc
TLGT
$1.85M 0.07%
+55,143
New +$1.75M
RARX
140
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$1.8M 0.07%
338,565
-17,672
-5% -$126K
ACIU icon
141
AC Immune
ACIU
$223M
$1.78M 0.07%
171,813
– –
EVH icon
142
Evolent Health
EVH
$348M
$1.75M 0.07%
122,500
– –
GKOS icon
143
Glaukos
GKOS
$9.83B
$1.7M 0.07%
55,079
– –
SNN icon
144
Smith & Nephew
SNN
$13.3B
$1.68M 0.07%
44,148
+3,965
+10% +$143K
STE icon
145
Steris
STE
$22.3B
$1.55M 0.06%
+16,612
New +$1.51M
LUMO
146
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.49M 0.06%
+22,781
New +$1.61M
ONCE
147
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$1.47M 0.06%
22,046
-16,660
-43% -$962K
AMRN
148
Amarin Corp
AMRN
$299M
$1.44M 0.06%
23,907
-23,908
-50% -$1.77M
XENE icon
149
Xenon Pharmaceuticals
XENE
$6.06B
$1.37M 0.05%
280,000
-70,000
-20% -$259K
RVNC
150
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.33M 0.05%
43,329
+11,104
+34% +$357K
4 5
6
7 8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, Tekla Capital Management held 197 positions worth $2.57B, down 0.83% from $2.59B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q1 2018 filing shows 37 new, 49 increased, 41 reduced and 10 closed positions. Its largest new stake was Esperion Therapeutics: 189,287 shares worth $13.7M. The largest sale was Gilead Sciences, an estimated $36.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Real Estate and Financials.

  • Tekla Capital Management's largest Q1 2018 buy was Esperion Therapeutics: 189,287 shares worth $13.7M.
  • Tekla Capital Management added most to Pfizer in Q1 2018, an estimated $39M increase.
  • Tekla Capital Management's biggest Q1 2018 reduction was Gilead Sciences, cutting an estimated $36.3M.
  • Tekla Capital Management fully exited NuVasive, Inc. in Q1 2018, selling an estimated $6.87M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.57B portfolio in Q1 2018.
  • Tekla Capital Management opened 37 new positions and closed 10 in Q1 2018.
  • Tekla Capital Management's portfolio value fell 0.83% quarter-over-quarter to $2.57B.

Based on Tekla Capital Management's 13F filing for Q1 2018, filed 14 May 2018.